Cinven to acquire the remaining 14.4% stake in Synlab.

Cinven, a private equity firms, agreed to acquire the remaining 14.4% stake in Synlab, an international medical diagnostics provider. Financial terms were not disclosed. Ephios Bidco, Cinven's investment vehicle, will announce the amount of the appropriate cash compensation separately to the Management Board of SYNLAB once the required valuation work has been completed.